NEWS & MEDIA
Featured
ASX News
Activities Report and Sales Note to Accompany Appendix 4C
Melbourne (Australia) – 27th July 2020. Telix Pharmaceuticals provides its Activities Report and Appendix 4C for the quarter ending 30th...
ASX News
Telix Pharmaceuticals Receives $11.4M R&D Tax Refund
Melbourne (Australia) – 21st July 2020. Telix Pharmaceuticals announces it has received an A$11.4M R&D tax refund in relation to...
ASX News
Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers
Melbourne (Australia) – 8th July 2020. Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion Medical
ASX News
Telix Granted FDA Breakthrough Therapy Designation for Renal Cancer Imaging Product
Melbourne (Australia) – 1st July 2020. Telix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal...
Corporate Spotlight
Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020
25th May 2020 - Clinical Spotlight | Telix Presents the IPAX-1 Study at the American Society of Clinical Oncology (ASCO)
Corporate Spotlight
The Seneffe Manufacturing Site – Telix’s Next Big Move in Europe
1st May 2020 - Corporate Spotlight | Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe...